Prescient Therapeutics

Prescient Therapeutics Limited (PTX) is a clinical stage oncology company developing novel compounds that show potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy. The company continues to develop its two drug candidates, PTX-100 and PTX-200, for potential new therapies to treat a range of cancers, including breast and ovarian cancer, as well as leukaemia.

Contact Details

Level 4 , 100 Albert Rd SOUTH MELBOURNE VIC 3205

03 9692 7222

www.ptxtherapeutics.com

Lists and Charts

Share price

Prescient Therapeutics
Closing price for the last 90 trading days

View ASX Chart

Total Shareholder Return as at 02/12/24

Rank	Company	1 Yr	5 Yr
1561^st	Credit Intelligence	-55.9%	-17.39%
1562^nd	Renascor Resources	-56%	38.38%
1563^rd	Prescient Therapeutics	-56%	-14.45%
1564^th	Micro-X	-56.01%	-24.28%
1565^th	Australasian Metals	-56.01%	0%

View Full List

1767 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Company Share Transactions

Company Activity

	NEW ROLE: Gavin Shepherd, Non-Executive Director	07 Aug 2024
	NEW ROLE: Ellen Feigal, Non-Executive Director	07 Aug 2024
	NEWS: Tagged in Where markets meet medicine; a biotech entrepreneur at the tip of the spear	14 Feb 2022
	NEWS: Tagged in Radiopharm scores coup with rare isotope supply deal	01 Feb 2022
	NEW ROLE: Said Sebti, Chief Scientific Officer	24 Nov 2020
	NEW ROLE: Terrence Chew, Chief Medical Officer	24 Nov 2020
	NEW ROLE: Said Sebt,	24 Nov 2020
	NEW ROLE: Allen J Ebens, Non-Executive Director	03 Nov 2020
	NEW ROLE: Melanie Leydin, Company Secretary	03 Nov 2020

News Articles

Related Information

Access to our data for Prescient Therapeutics is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Prescient Therapeutics is included in 1 list - Public Companies - non WA.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

Subscribe today